The Cancer Letter

Inside information on cancer research and drug development

In Brief

Katalin Karikó, Drew Weissman awarded 2023 Nobel Prize in Physiology or Medicine for mRNA vaccine research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Katalin Karikó (left) and  Drew Weissman (right)Photo credit: Niklas Elmehed © Nobel Prize Outreach

Katalin Karikó and Drew Weissman were jointly awarded the 2023 Nobel Prize in Physiology or Medicine “for their discoveries concerning base modifications that enabled the development of effective mRNA vaccines against COVID-19.”

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Victor Ambros and Gary Ruvkun share 2024 Nobel Prize in Physiology or Medicine

Victor AmbrosPhoto credit: Niklas Elmehed © Nobel Prize OutreachGary RuvkunPhoto credit: Niklas Elmehed © Nobel Prize OutreachVictor Ambros and Gary Ruvkun were jointly awarded the 2024 Nobel Prize in Physiology or Medicine from the Nobel Assembly at the Karolinska Institutet. The two scientists are being honored for their discovery of microRNA and its role in post-transcriptional gene regulation.
Clinical Roundup

mRNA biomarkers and AI algorithm detect colorectal cancer

Topline results from a pooled clinical study show that Mainz Biomed’s portfolio of proprietary novel gene expression (mRNA) biomarkers can be used in a next generation version of the company’s colorectal cancer screening tool. The study included new patients and subjects from Mainz Biomed’s ColoFuture (Europe) and eAArly DETECT (U.S.) clinical trials. The topline results confirm the positive efficacy results previously reported with a sensitivity for colorectal cancer of 92% with a specificity of 90% and a sensitivity for advanced adenoma of 82%, the company said.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account